โ† All deals

UNITED THERAPEUTICS CORPORATION

Public Equity (NASDAQ)Public CompanyPharmaceuticalBiotech
๐Ÿ“ Silver Spring, Maryland, United Statesโ€ข Founded 1996
StreetZero Signal 65
Be the first to signal interest

About UNITED THERAPEUTICS CORPORATION

United Therapeutics Corporation is a public benefit corporation focused on developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. Founded in 1996 and headquartered in Silver Spring, Maryland, the company has six FDA-approved therapies treating pulmonary arterial hypertension (PAH) and related conditions. It operates in the pharmaceutical manufacturing sector and is listed on NASDAQ under UTHR. The company emphasizes innovation for rare, deadly diseases and was the first publicly-traded biotech or pharmaceutical firm to adopt public benefit corporation status.

LATEST FUNDINGRule 144
$4.7M
Announced 2026-11-19
TOTAL RAISED2.50B USD
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for UNITED THERAPEUTICS CORPORATION.

Free plan includes 3 full deal profiles every month.

EMPLOYEESโ€”
FOUNDED1996
HQSilver Spring, Maryland, United States
Industry
Public Equity (NASDAQ)
Tags
Public CompanyPharmaceuticalBiotechPAH

Investors

Not disclosed in the source filing. Form D filings do not list investors โ€” StreetZero surfaces them from news where available.

Key highlights

  • Public benefit corporation with mission to develop therapies expanding transplantable organs.
  • Six FDA-approved therapies for pulmonary arterial hypertension.
  • Completed $2.50B Post-IPO Debt round in 2025.
  • Acquired Miromatrix Medical for $91M and Thymmune Therapeutics for $140M.
  • Authorized $2B share repurchase program through 2027.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account